Gekko-sulfated glycopeptide decreases bFGF secretion and binding to its low affinity receptor heparin/heparan sulfate, inhibits bFGF stimulated proliferation and migration of endothelial cells, and thus inhibits angiogenesis and tumor growth in liver cancer [148] (Figure 1, Table 3). Here, FGF2 is linked to liver cancer.